272 related articles for article (PubMed ID: 31791361)
1. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.
Kałużna M; Trzeciak I; Ziemnicka K; Machaczka M; Ruchała M
Orphanet J Rare Dis; 2019 Dec; 14(1):275. PubMed ID: 31791361
[TBL] [Abstract][Full Text] [Related]
2. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease.
Nascimbeni F; Dalla Salda A; Carubbi F
Blood Cells Mol Dis; 2018 Feb; 68():74-80. PubMed ID: 27839982
[TBL] [Abstract][Full Text] [Related]
3. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
4. Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy.
Doneda D; Lopes AL; Teixeira BC; Mittelstadt SD; Moulin CC; Schwartz IV
Clin Nutr; 2015 Aug; 34(4):727-31. PubMed ID: 25239509
[TBL] [Abstract][Full Text] [Related]
5. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.
Rosenbloom B; Balwani M; Bronstein JM; Kolodny E; Sathe S; Gwosdow AR; Taylor JS; Cole JA; Zimran A; Weinreb NJ
Blood Cells Mol Dis; 2011 Jan; 46(1):95-102. PubMed ID: 21067946
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan.
Narita A; Koto Y; Noto S; Okada M; Ono M; Baba T; Sagara R; Sakai N
Orphanet J Rare Dis; 2024 Jan; 19(1):11. PubMed ID: 38183145
[TBL] [Abstract][Full Text] [Related]
7. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
8. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).
Chérin P; Rose C; de Roux-Serratrice C; Tardy D; Dobbelaere D; Grosbois B; Hachulla E; Jaussaud R; Javier RM; Noël E; Clerson P; Hartmann A
J Inherit Metab Dis; 2010 Aug; 33(4):331-8. PubMed ID: 20532983
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy.
Ersoy M; Pişkinpaşa H
J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971
[TBL] [Abstract][Full Text] [Related]
10. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry.
Mikosch P; Reed M; Stettner H; Baker R; Mehta AB; Hughes DA
Mol Genet Metab; 2009 Mar; 96(3):113-20. PubMed ID: 19147383
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.
Herrera S; Pérez-López J; Moltó-Abad M; Güerri-Fernández R; Cabezudo E; Novelli S; Esteve J; Hernández A; Roig I; Solanich X; Prieto-Alhambra D; Nogués X; Díez-Pérez A
J Bone Miner Res; 2017 Jul; 32(7):1575-1581. PubMed ID: 28263001
[TBL] [Abstract][Full Text] [Related]
12. Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients.
Serai SD; Naidu AP; Andrew Burrow T; Prada CE; Xanthakos S; Towbin AJ
Mol Genet Metab; 2018 Mar; 123(3):357-363. PubMed ID: 29361370
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cellular cobalamin metabolism in Gaucher disease.
Basgalupp SP; Siebert M; Ferreira C; Behringer S; Spiekerkoetter U; Hannibal L; Schwartz IVD
BMC Med Genet; 2020 Jan; 21(1):12. PubMed ID: 31931749
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and endocrine abnormalities in patients with nonunions.
Brinker MR; O'Connor DP; Monla YT; Earthman TP
J Orthop Trauma; 2007 Sep; 21(8):557-70. PubMed ID: 17805023
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells and monocyte subsets in children with Gaucher disease.
Zahran AM; Saad K; Abdallah AM; Gad EF; Abdel-Raheem YF; Zahran ZAM; Nagiub Abdelsalam EM; Elhoufey A; Alruwaili T; Mahmoud KH; Elsayh KI
Pediatr Res; 2021 Sep; 90(3):664-669. PubMed ID: 33469171
[TBL] [Abstract][Full Text] [Related]
16. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.
Gervas-Arruga J; Cebolla JJ; de Blas I; Roca M; Pocovi M; Giraldo P
PLoS One; 2015; 10(5):e0126153. PubMed ID: 25978039
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment.
Iaccarino Idelson P; Speranza E; Marra M; Pasanisi F; Sammarco R; Galletti F; Strazzullo P; Barbato A
Nutrients; 2022 Aug; 14(15):. PubMed ID: 35956356
[TBL] [Abstract][Full Text] [Related]
18. Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1.
Markuszewska-Kuczynska A; Klimkowska M; Regenthal S; Bulanda A; Kämpe Björkvall C; Machaczka M
Folia Histochem Cytobiol; 2015; 53(1):62-9. PubMed ID: 25736845
[TBL] [Abstract][Full Text] [Related]
19. Activated and Memory T Lymphocytes in Children with Gaucher Disease.
Zahran AM; Eltayeb AA; Elsayh KI; Saad K; Ahmad FA; Ibrahim AIM
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):263-269. PubMed ID: 27638481
[TBL] [Abstract][Full Text] [Related]
20. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
Stirnemann J; Belmatoug N; Camou F; Serratrice C; Froissart R; Caillaud C; Levade T; Astudillo L; Serratrice J; Brassier A; Rose C; Billette de Villemeur T; Berger MG
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
